Form 4: Vaxcyte COO Jim Wassil Executes Option, Sells Shares Under 10b5-1 Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On October 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., exercised a stock option to acquire 8,000 shares of common stock at a price of $2.42 per share.
• Simultaneously, Wassil sold a total of 8,000 shares in four separate transactions, with prices ranging from $112.805 to $115.17 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 1, 2024.
• Following these transactions, Wassil directly owns 200,646 shares of Vaxcyte common stock and 34,638 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing simply reports transactions. The 10b5-1 plan suggests pre-planned sales, reducing potential negative interpretations.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes be perceived negatively by investors.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are often scrutinized by investors for insights into management's perspective on the company's future prospects.

Stakeholder Impact

• Shareholders may react to the stock sales, although the 10b5-1 plan should mitigate concerns.

Key Dates